China FDA Rejections For Generic Drugs Show Tightening Quality Noose
This article was originally published in SRA
Executive Summary
The rejection by the China Food and Drug Administration of 11 drug applications filed by eight domestic companies earlier this month was due to inadequate or suspect clinical data, and generics accounted for the majority of the unqualified filings1.